Interestingly, even though eliciting the strongest anti-tumor response, the DAP-10/CD27 G3 CAR-T cells tended to be present at lower frequencies compared to CD28 G2 CAR-T cells in vivo. This evidence concerns the gene CD27 and neoplasm.